《Enanta Corporate Presentation JPM January 10 2023 Final.pdf》由会员分享,可在线阅读,更多相关《Enanta Corporate Presentation JPM January 10 2023 Final.pdf(36页珍藏版)》请在三个皮匠报告上搜索。
1、Corporate PresentationJ.P.Morgan 41stAnnual Healthcare ConferenceJanuary 10,2023 2023 Enanta Pharmaceuticals,Inc.|This presentation contains forward-looking statements concerning our business,operations and financial performance andcondition,as well as our plans,objectives and expectations for our r
2、esearch and development programs,our business and theindustry in which we operate.Any statements contained herein that are not statements of historical facts may be deemed to beforward-looking statements.In some cases,you can identify forward-looking statements by terminology such as“aim,”“anticipat
3、e,”“assume,”“believe,”“contemplate,”“continue,”“could,”“due,”“estimate,”“expect,”“goal,”“intend,”“may,”“objective,”“plan,”“predict,”“potential,”“positioned,”“seek,”“should,”“target,”“will,”“would,”and other similar expressions that are predictions of orindicate future events and future trends,as wel
4、l as other comparable terminology.These forward-looking statements include,butare not limited to,statements about overall trends,royalty revenue trends,research and clinical development plans and prospects,liquidity and capital needs and other statements of expectations,beliefs,future plans and stra
5、tegies,anticipated events or trends,and similar expressions.These forward-looking statements are based on our managements current expectations,estimates,forecasts and projections about our business and the industry in which we operate and our managements beliefs andassumptions.These forward-looking
6、statements are not guarantees of future performance or results and involve known andunknown risks,uncertainties and other factors that are in some cases beyond our control.As a result,any or all of our forward-looking statements in this presentation may turn out to be inaccurate.Please refer to the
7、risk factors described or referred to in“Risk Factors”in Enantas most recent Quarterly Report on Form 10-Q,and other periodic reports filed with the Securities and Exchange Commission.Enanta cautions investors not to place unduereliance on the forward-looking statements contained in this presentatio
8、n.These statements speak only as of the date of thispresentation,and Enanta undertakes no obligation to update or revise these statements,except as may be required by law.Forward Looking Statements Disclaimer2 2023 Enanta Pharmaceuticals,Inc.|Using a proven,chemistry-driven approach to develop best-
9、in-class small molecule drugs for viral infectionsA Proven Approach to Drug DiscoveryProven Track Record of SuccessRobust Clinical Stage PipelineStrong balance sheet and royalties to fund robust pipeline$278.5M in cash at September 30,2022Glecaprevir HCV protease inhibitor in MAVYRET/MAVIRET$86.2M i
10、n fiscal 2022 royalties on HCV regimensStrong Balance Sheet RSV:Phase 2 in pediatric patients(RSVPEDs)Phase 2b in adult stem cell transplant patients(RSVTx)Phase 2b in high-risk adults(RSVHR)Phase 1 in healthy volunteers with second RSV candidateCOVID-19:Phase 2(SPRINT)HBV:Two Phase 1b studies34Leve
11、raging our core strength in Hepatitis C to become a leader in oral treatments for viral infectionsSeveral new therapeutic areas with goal of building multiple approaches in eachOur Therapeutic FocusRSVhMPVHBVCOVID-19HCV 2023 Enanta Pharmaceuticals,Inc.|PRODUCT CANDIDATEDISCOVERYPRECLINICALPHASE 1PHA
12、SE 2PHASE 3MARKETVirology:LiverHCVProtease InhibitorHBVCore InhibitorVirology:RespiratoryRSVN-Protein InhibitorL-Protein InhibitorDual hMPV/RSVNon-Fusion InhibitorCOVID-193CL Protease InhibitorPL Protease InhibitorFor Out-licenseNASHFXR AgonistsEDP-305(Phase 2),EDP-297(Phase 1)EDP-938 RSVHR*Fixed-do
13、se combination contains glecaprevir and AbbVies NS5A inhibitor,pibrentasvir.Marketed by AbbVie as MAVYRET(U.S.)and MAVIRET(ex-U.S.).Enanta Pipeline EDP-323EDP-938 RSVPEDsEDP-938 RSVTxGlecaprevir-containing pangenotypic 2-DAA combo*EDP-5145EDP-235 SPRINT6Leveraging our core strength in Hepatitis C to
14、 become a leader in oral treatments for viral infections Several new therapeutic areas with goal of building multiple approaches in eachOur Therapeutic FocusRSVhMPVHBVCOVID-19HCV 2023 Enanta Pharmaceuticals,Inc.|Higher risk populations for severe illness:Young infants and childrenPremature babiesOld
15、er adults especially those 65+yearsPeople with chronic lung disease or certain heart problemsPeople with weakened immune systems(e.g.HIV,organ transplant,chemotherapy)Respiratory Syncytial Virus(RSV)RSV at a Glance Children 65 years233M global cases3M global hospitalizations177K U.S.hospitalizations
16、101K global deaths14K U.S.deathsCauses severe lung infections,including bronchiolitis(infection of small airways in the lungs)and pneumonia(an infection of the lungs).No safe and effective treatments.7Sources:1.https:/ 2.https:/www.cdc.gov/rsv/high-risk/older-adults.html 2023 Enanta Pharmaceuticals,
17、Inc.|EDP-938 is the only N-inhibitor in later stage clinical developmentNon-fusion approach directly targets viral replication vs.entryGranted Fast Track designation by FDAStrong preclinical virologic profileNanomolar inhibitor of both RSV-A and RSV-BAntiviral potency across all clinical isolates te
18、stedHigh-barrier to resistance in vitroSynergy with other drug mechanisms(e.g.fusion and L-inhibitors)Active against virus variants resistant to other mechanismsRobust efficacy data in non-human primate modelEDP-938:N-Protein Inhibitor for RSV8 2023 Enanta Pharmaceuticals,Inc.|EDP-938:Summary of Dat
19、a Across Completed Clinical StudiesSafety and Pharmacokinetic SummaryGenerally safe and well-tolerated;AEs infrequent,generally mild,and resolved in follow-upNo serious or severe AEsConsistent safety profile observed in approximately 500 subjects exposed to dateMean trough concentrations were approx
20、imately 20-40 x higher than EC90Efficacy SummaryPhase 2a challenge study:highly statistically significant(p0.001)reductions in RSV viral load and clinical symptoms compared to placebo after 5 days of treatmentRSVP study in otherwise healthy adults with community-acquired,mild,self-resolving RSVDid n
21、ot meet primary endpoint of clinical symptom reduction or secondary antiviral endpoints Statistically significant percent of subjects achieved undetectable RSV RNA at end of treatmentAlthough treated within 48 hours of symptom onset,viral load and symptoms had already peaked and were declining,indic
22、ating infection resolves quickly in this otherwise healthy population9 2023 Enanta Pharmaceuticals,Inc.|PropertiesEDP-938Ziresovir/AK-059Sinsunatovir/RV5211MechanismN inhibitorFusion inhibitorFusion inhibitorPre-clinical Effectiveness After InfectionYesNoNoClinical Efficacy(challenge study4)Viral Lo
23、ad Reduction275%(p0.001)NA55%(p=0.007)Symptoms371%(p0.02)NA71%(p=0.018)Resistance BarrierHighLowLowDosing Frequency 5 days;800mg QD5 days;BID5 days;200mg BIDStage of DevelopmentGlobal Phase 2Asia Phase 3Global Phase 2EDP-938:Potential to be the Leading Antiviral Treatment for RSV10Only includes comp
24、ounds in development with clinical data in patients1.DeVincenzo et al,2020;AAC;64(2);2.%reduction in viral load(VL)area under the curve(AUC)as measured by qPCR;3.%reduction in totalsymptom score(TSS)AUC;4.Data from selected dose moving forwardNA=not available;challenge study not performed 2023 Enant
25、a Pharmaceuticals,Inc.|Goal:Treat patients at high-risk for developing severe infection leading to hospitalization or death,populations with the most significant unmet needInfants and young childrenImmunocompromised(e.g.;HSC,lung transplant)ElderlyChronic heart or lung disease(e.g.COPD,CHF,asthma)ED
26、P-938 Development Plans:Treatment for Patients at High-Risk for Severe RSV Infection11High-risk populations have reduced RSV immunity,resulting in a higher and longer duration of viral load and greater disease severity,allowing a bigger window to observe benefit 2023 Enanta Pharmaceuticals,Inc.|Ongo
27、ing Phase 2 Clinical Trials:RSVPEDs and RSVTx90 patientsAge 28 days 36 monthsDosed in 4 age cohortsDouble-Blinded Treatment Phase5 daysPart 1:MAD in 4 age cohortsPart 2:Selected dose from Part 1 across 4 age cohortsDay 1Day 5Day 28Primary Objective:Effect of EDP-938 on development of LRTC in HCT sub
28、jects with acute RSV URTISecondary Objectives:Viral load,progression to respiratory failure or all-cause mortality,PRO,PK and safetyDouble-Blinded Treatment Phase21 daysPlacebo(QD)800mg(QD)Day 1Day 49Day 21LRTC:lower respiratory tract complication;HCT:hematopoietic cell transplant;URTI:upper respira
29、tory tract infection;PRO:patient reported outcomes;PK:pharmacokinetics23 Day Follow-upPrimary Objective,Part 1:Safety and PK of EDP-938Primary Objective,Part 2:Antiviral activity of EDP-93812200 adult HCT recipientsAge 18 75 years28 Day Follow-up 2023 Enanta Pharmaceuticals,Inc.|Newest Phase 2 Study
30、:RSVHR(High Risk Populations)13Primary Objective:Time to resolution of RSV LRTD symptoms as assessed by RiiQ symptom scale through Day 33Secondary Objectives:PROs,MAVs,viral load,antibiotic use,bronchodilator use,corticosteroid use,hospitalization,ICU,mechanical ventilation,all cause mortality,pharm
31、acokinetics and safetyDouble-Blinded Treatment Phase5 daysPlacebo(QD)800mg(QD)Day 1Day 33Day 5180 adults with at least one of the following:COPDCongestive heart failureAsthma*Age 65*28 Day Follow-up*The total proportion of subjects either 65 years of age or patients with asthma combined will be capp
32、ed at 20%.LRTD:lower respiratory tract disease;RiiQ:Respiratory Infection Intensity and Impact Questionnaire,PRO:patient reported outcomes;MAVs:medically attended visits 2023 Enanta Pharmaceuticals,Inc.|Novel,oral,selective direct-acting antiviral targeting the RSV L-proteinRSV L-protein is a viral
33、RNA-dependent RNA polymerase that contains multiple enzyme activities required for RSV replicationPotential to be used alone or in combination with other classes of RSV inhibitors,such as EDP-938Additive to synergistic with F-,N-,L-inhibitors and ribavirinNot expected to have cross resistance with o
34、ther mechanismsNanomolar potency against RSV-A and RSV-BPhase 1 readout targeted for 1H 2023EDP-323:RSV L-Protein Inhibitor14.2023 Enanta Pharmaceuticals,Inc.|Sub-nanomolar inhibition of RSV replication in a range of cell typesActive against both major RSV subtypesProtects mice in a dose-dependent m
35、anner from RSV infection as quantified by both virological and pathological endpointsWell-absorbed with good plasma exposure across multiple preclinical speciesHigh permeability/absorption potential in humansEDP-323 is a Potent Inhibitor of RSV Replication In Vitro With Excellent Preclinical Pharmac
36、okinetics15VirusCell TypeEC90(nM)RSV-A LongpHAEC ALI0.27RSV-B VR-955pHAEC ALI0.33RSV-A LongHBEC0.16RT-qPCR readout pHAEC ALI:primary human airway epithelial cells in air-liquid interface cultureHBEC:human bronchial epithelial cells50%cytotoxic concentration(CC50)at 5 days=17,000 29,000 nM 2023 Enant
37、a Pharmaceuticals,Inc.|hMPV at a Glance1Serious respiratory infections can occur in children under 5 years oldSecond most common cause of lower RTIs in children(behind RSV)Reinfection with hMPV occurs throughout lifeParamyxovirus closely related to RSVhMPV replication dependent on several viral prot
38、eins that form a multiprotein complex in cellsMultiple potential targets for hMPV drug discoveryEnanta nanomolar hMPV inhibitor leads under active optimization Human Metapneumovirus(hMPV)Important cause of respiratory tract infections(RTIs),particularly in children,the elderly and immunocompromised
39、individuals.No approved vaccine or therapeutics available.Source:1.https:/www.ncbi.nlm.nih.gov/pmc/articles/PMC1539100/16 2023 Enanta Pharmaceuticals,Inc.|hMPV/RSV Dual Inhibitor Discovery Program17CPE:cytopathic effect;qPCR:quantitative polymerase chain reactionLLC-MK2:monkey kidney;HEp-2:human epi
40、thelium cells;pHAEC:primary human airway epithelial cellsVirusGenotypeAssayEndpoint/CellsPotency(EC90nM)hMPVA1CPE/LLC-MK218A236B10.6B24A2qPCR/pHAEC17RSVACPE/HEp-20.4B0.1Enanta is developing novel,oral,direct-acting antivirals specifically designed to target both hMPV and RSVPotential for a broader s
41、pectrum antiviralRespiratory infections diagnosed as either hMPV or RSV treated with a single agentEnanta has discovered dual inhibitors with nanomolar potencyActivity maintained against multiple genotypes and strains of hMPV and RSV in a range of cell typesPrototype Inhibitor:Dual-001 2023 Enanta P
42、harmaceuticals,Inc.|Prototype Dual Inhibitor Blocks Both hMPV and RSV Replication 18N=10-12per cohort*p0.01,*p4)Supported by Phase 1 PK data at 200mg and 400mg QDPhase 2 study(SPRINT)readout targeted for 1H 2023EDP-235:Oral Protease Inhibitor Designed for COVID-1920 2023 Enanta Pharmaceuticals,Inc.|
43、EDP-235:Highly Potent 3CLpro Inhibitor and Retains Activity Against SARS-CoV-2 VariantsAssayVariant/Lineage(mutation)Potency(EC90,nM)Biochemical Activity3CLpro FRET(IC50)Omicron(P132H)B.1.1.529,BA.2,BA.5,BA.2.75,BQ.1,BQ1.1,XBB.14.1 0.8Alpha Original/Delta*B.1.617.25.8 3.7B.1.1.318(T21I)2.0 0.1Beta B
44、.1.351(K90R)2.8 0.9Beta B.1.351.2(K90R/A193V)5.4 1.0B.1.617.3(A194S)5.7 0.5C.36.3(G15S)4.7 2.5Zeta P.2(L205V)3.4 1.0Live VirusVero E6+PGPi,CPE readout(EC90)Omicron B.1.1.5295.1(n=1)Delta B.1.617.29.1 2.9Alpha Original11 8FRET:fluorescence resonance energy transfer,P-gpi:P-glycoprotein inhibitor CP-1
45、00356(2 M),CPE:cytopathic effectValues average of replicate experiments except where noted*3CLpro sequences for the ancestral A lineage and B.1.617.2(Delta)variant are identical21 2023 Enanta Pharmaceuticals,Inc.|Antiviral Treatment EffectEDP-235 treatment of SARS-CoV-2 infected animals resulted in
46、a rapid and robust decline in viral replicationTransmission PreventionInfected,vehicle-treated animals went on to infect healthy co-housed contact animals(black lines in graph)Infected,EDP-235 treated animals did not infect healthy co-housed contact animals(red/green lines)Supports the potential for
47、 EDP-235 to reduce household transmissionEDP-235 is Efficacious in a Ferret Model of COVIDRobust Antiviral Treatment Effect and Prevention of Transmission22TCID50:50%tissue culture infectious doseLive Virus Detected in Nasal LavageDays Post-Infection 2023 Enanta Pharmaceuticals,Inc.|Preclinical Prop
48、ertiesEDP-2351Nirmatrelvir2PBI-04513Ensitrelvir4Molnupiravir5AT-5276MechanismProteaseProteaseProteaseProteasePolymerasePolymerasePotency(nM)*Enzyme IC505.8192513n/an/aVero Cell EC50 5.1754869(Delta)1410*n/aVero Cell EC9011155n/an/an/a470*(In pHAEC)Oral Bioavailability795%34 50%n/a97%36 56%n/aLung Pe
49、netration84.10.8910.791.80.8Projected Efficacious Dose 200 or 400 mg QD300 mg/100 mg ritonavir BID700 mg BID 375 mg(D1)/125 mg(D2-5)QD 800 mg Q12h550mg BIDEDP-235 Profile Suggests Potential for Best-in-Class Antiviral Treatment for SARS-CoV-2 Infection231.Jiang et al.,ISIRV Poster#120,Oct 19,20212.O
50、wen et al.,Science November 2021;Owen et al.ACS Spring 2021 meeting;EUA fact sheet for healthcare providers3.Pardes ICAR Presentation March 2022 4.Tachibana,et al.,ISIRV oral presentation,Oct 20,2021;Unoh,et al.,bioRxiv 2022;Sasaki,et al.,bioRxiv 2022;Yotsuyanagi,et al.,ECCMID oral presentation,Apr
51、24,20225.Grobler et al.,ID Week 2021,Poster 543;Painter et al.,Antiviral Research Nov 20196.Good et al.,AAC,2021;Atea 2Q2021 earnings presentation;Atea 1Q2022 earnings presentation;Atea 2Q2022 earnings presentation7.Oral bioavailability in rats for EDP-235,nirmatrelvir,and ensitrelvir;in mice for mo
52、lnupiravir8.AUC lung to plasma ratio in rats(EDP-235,nirmatrelvir,ensitrelvir),mice(molnupiravir);C12 lung to plasma ratio in humans for AT-5279.Data for nirmatrelvir and ensitrelvir generated by Enanta*All potency values versus ancestral(A)lineage unless indicated*Data from N-hydroxycytidine(NHC):m
53、olnupiravir is prodrug of NHC*Data from AT-511(AT-527 is the hemi-sulfate salt of AT-511)pHAEC:primary human airway epithelial cellsn/a:not available 2023 Enanta Pharmaceuticals,Inc.|Randomized,double-blind,placebo-controlled Phase 1 study in healthy volunteers(n=72)Single and multiple ascending dos
54、es(SAD:50 800mg and MAD:200 800mg once-daily)Generally safe and well-tolerated up to 400mg for up to 7 daysMajority of AEs were mild,with the most frequent being headache and GI related symptomsThree subjects discontinued due to an AE:one moderate headache in the 400mg fasted cohort,one severe heada
55、che in the 800mg fed cohort and one grade 3 ALT/grade 2 AST elevation in the 800mg fed cohortPharmacokinetics:200mg or 400mg taken once-daily with food achieved target exposuresExposure increased proportionally with increasing single and multiple dosesConsistent half-life ranging from 13 to 22 hours
56、 Exposure enhanced with food administration regardless of fat contentEDP-235:Phase 1 Safety,Tolerability and Pharmacokinetics24*Multiples by which mean trough drug plasma levels at steady state are higher than protein adjusted EC90 as measured in Vero cellsMeasured Plasma Drug Multiples*Variant200mg
57、 QD400mg QDAlpha3x6xOmicron7x13xPredicted Lung Drug Multiples*Variant200mg QD400mg QDAlpha12x24xOmicron28x52x 2023 Enanta Pharmaceuticals,Inc.|SPRINT:SARS-Cov-2 PRotease INhibitor Treatment Phase 2 Study for EDP-23525Day 1Day 5Day 3328 Day Follow-upPlacebo(QD)EDP-235 200mg(QD)EDP-235 400mg(QD)Screen
58、ing200 patients*1:1:1 Randomization(66 per group)Double Blinded Treatment Phase5 daysPrimary Objective:Evaluation of safety and tolerabilitySecondary Objectives:Evaluation of virologic endpoints,clinical symptoms and outcomes,and pharmacokinetics*Non-hospitalized adults with mild or moderate COVID-1
59、9 and symptom onset within 5 days,who are not at increased risk for developing severe disease and have not been vaccinated or infected with SARS-CoV-2 less than 90 days of enrollment 2023 Enanta Pharmaceuticals,Inc.|Potent antiviral activity in vitro against SARS-CoV-2 variants,including Omicron var
60、iantsGenerally safe and well-tolerated up to 400mg dose up to 7 daysEfficacious dose of 200mg or 400mg once-daily,without the need for boosting(e.g.ritonavir)200mg:plasma levels 3x and 7x higher than EC90of Alpha and Omicron variants,respectively400mg:plasma levels 6x and 13x higher than EC90of Alph
61、a and Omicron variants,respectivelyProjected to have 4x higher drug levels in lung tissue compared to plasmaGood distribution into other key target tissues*providing the potential to impact post-treatment rebound and/or possible sites of ongoing replication linked to long COVIDPhase 2 study(SPRINT)r
62、eadout targeted for 1H 2023EDP-235 Profile Suggests Potential for Best-in-Class Antiviral Treatment for SARS-CoV-2 Infection26*adipose,heart,liver,salivary gland,and lung alveolar macrophagesEmerging data supports convenient dosing regimen,targeting a one pill,once-a-day treatment active against COV
63、ID-19 variants of concern 2023 Enanta Pharmaceuticals,Inc.|New Program Developing SARS-CoV-2 PLpro InhibitorsEnanta is developing novel,oral,direct-acting antivirals specifically designed to target the SARS-CoV-2 PLpro SARS-CoV-2 protease required for viral replication(distinct from 3CLpro)Acts to s
64、uppress the innate immune response Inhibition of PLpro blocks viral replication and has the potential to restore the dysregulated immune response to SARS-CoV-2 infectionMechanism distinct from 3CLpro inhibition(EDP-235)and therefore has the potential to be used alone or in combinationModified from h
65、ttps:/viralzone.expasy.org/764?outline=complete_by_proteinCONFIDENTIALBiochemical AssayLive Virus Omicron BA5.1IC50=3.7+0.1 nMEC50=76+28 nMBiochemical assay:measures cleavage using ancestral SARS-CoV-2 lineageLive virus assay:Vero E6-TMPRSS2 cells;endpoint-viral load reduction by TCID50assayPrototyp
66、e Inhibitor:PLpro-0012728Leveraging our core strength in Hepatitis C to become a leader in oral treatments for viral infections Several new therapeutic areas with goal of building multiple approaches in eachOur Therapeutic FocusRSVhMPVHBVCOVID-19HCV 2023 Enanta Pharmaceuticals,Inc.|In 2019,hepatitis
67、 B resulted in an estimated 820,000 deaths,mostly from cirrhosis and hepatocellular carcinoma(primary liver cancer)1Current treatments rarely give true curesInterferon is 10%effective,but with side effects2Reverse-transcriptase inhibitors effective at reducing viral load,but low cure rates(1%or lowe
68、r)and treatment for life to improve cirrhosis or HCC outcomes3Hepatitis B Virus(HBV)HBV at a Glance U.S.850K 2M people4Europe and European Economic Area4.7M people5Worldwide290M people6Sources:1.https:/www.who.int/news-room/fact-sheets/detail/hepatitis-b 2.https:/www.ncbi.nlm.nih.gov/pmc/articles/PM
69、C5401664/3.https:/pubmed.ncbi.nlm.nih.gov/30342034/4.https:/ 5.https:/www.ncbi.nlm.nih.gov/pmc/articles/PMC5356432/6.https:/pubmed.ncbi.nlm.nih.gov/29599078/Potentially life-threatening liver infection29 2023 Enanta Pharmaceuticals,Inc.|EDP-514:HBV Core Inhibitor30A novel core inhibitor that display
70、s potent anti-HBV activity at multiple points in the HBV lifecycleGranted Fast Track designation by FDAIn vitro Potent anti-HBV activity in HBV expressing stable cell lines Capable of preventing the establishment of cccDNA Pan-genotypic activityIn vivo Favorable tolerability and pharmacokinetic prof
71、ile Over 4-log reduction in HBV viral titers with 12 weeks of treatment in a chimeric liver mouse modelPhase 1a Healthy volunteer SAD/MAD Generally safe and well tolerated for up to 14 days All reported treatment emergent adverse events of mild severity Pharmacokinetics supportive of once-daily dosi
72、ng with no food effect 2023 Enanta Pharmaceuticals,Inc.|Randomized,double-blind studies in NUC-suppressed(n=24)or viremic(n=24)HBV patientsPatients dosed for 28 days with 200mg,400mg or 800mg of EDP-514 or placeboEDP-514 was safe and well-tolerated in both patient populations at all doses up to 28 d
73、aysPharmacokinetics support once-daily dosing,with trough concentrations of 20-fold the paEC50Significant reductions in HBV DNA and RNA across patient populationsNUC-suppressed patients:mean reduction in HBV RNA of up to 1 log compared with 0.2 log in placebo Maximum reduction of 2.3 log(HBeAg-)and
74、2.8 log(HBeAg+)was observed in patients receiving EDP-514 as compared with 1.2 log in placeboViremic patients:Mean reductions in HBV DNA of 3-3.5 logs across dose groups vs 0.2 log in placeboMean reductions in HBV RNA of 2-3 logs across dose groups vs 0.02 log in placeboEDP-514:Two Positive Phase 1b
75、 Studies in HBV Patients31paEC50:protein-adjusted EC5032Leveraging our core strength in Hepatitis C to become a leader in oral treatments for viral infectionsSeveral new therapeutic areas with goal of building multiple approaches in eachOur Therapeutic FocusRSVhMPVHBVCOVID-19HCV 2023 Enanta Pharmace
76、uticals,Inc.|ProductRegimenEnanta AssetEconomics*2-DAA (ABBV)glecaprevir(PI)Double-digit royalty on 50%of net salesGlecaprevir:Our Licensed Protease Inhibitor for Hepatitis C Virus33*Enanta also receives royalties on paritaprevir sales(30%of VIEKIRA 3DAA sales,same tiers)Royalty Rate(annual)Glecapre
77、vir Sales(50%of MAVYRETnet sales)Calendar 2022 HCV RoyaltiesQ4 TBDQ3$20.3MQ2$19.5MQ1$18.7M$500M$750M$1.0B$2.5B10%12%14%17%20%2023 Enanta Pharmaceuticals,Inc.|Financial Highlights34($In millions except per share amounts)Fiscal Year EndedSept.30,2022Fiscal Quarter EndedSep.30,2022Total Revenues$86.2$2
78、0.3R&D Expenses$164.5$34.8G&A Expenses$45.5$12.6Net Loss$(121.8)$(26.3)Net Loss per Diluted Common Share$(5.91)$(1.27)Balance SheetCash,Cash Equivalents and Marketable Securities$278.5$278.5 2023 Enanta Pharmaceuticals,Inc.|SARS-CoV-2 EDP-235(3CLpro):Report Phase 2(SPRINT)data in 1H 2023 EDP-235(3CL
79、pro):Initiate Phase 3 in 2H 2023 PLpro:Optimize lead candidatesRespiratory Syncytial Virus EDP-938:Continue Phase 2 recruitment in high-risk patient populations EDP-323:Report Phase 1 data in 1H 2023Human Metapneumovirus&Respiratory Syncytial Virus Select dual-acting clinical candidate in 4Q 2023Key Catalysts 2023Virology RespiratoryHepatitis B Virus Select third mechanism for HBV combination regimen with EDP-514Virology L